Subscribe to RSS
DOI: 10.1055/a-2190-3735
Morbidity in Patients with Chronic Adrenal Insufficiency – Cardiovascular Risk Factors and Hospitalization Rate Compared to Population Based Controls
Funding Information Deutsche Forschungsgemeinschaft (CRC/Transregio 205 “The Adrenal: Central Relay in Health and Disease”, project number 314061271). Else Kröner-Fresenius Stiftung and the Eva Luise Köhler Stiftung.![](https://www.thieme-connect.de/media/hmr/202401/lookinside/thumbnails/2023-07-0298_10-1055-a-2190-3735-1.jpg)
Abstract
Patients with adrenal insufficiency (AI) have been found to have increased cardiovascular morbidity, partly associated with nonphysiologic glucocorticoid replacement. We included two separate cohorts (cohort 1 n=384 patients, cohort 2 n=180 patients) of patients with chronic primary and secondary AI under standard replacement therapy and compared them to two age- and sex-matched population-based studies (SHIP-TREND/DEGS). Odds ratios with 95% CI for hypertension, hyperlipidemia/HLP, type 2 diabetes/T2DM, obesity, and hospitalization with adjustment for confounders were evaluated by logistic regression. Patient cohort 1 had significantly lower ORs for obesity [0.4 (0.3–0.6), p<0.001] and hypertension [0.5 (0.3–0.6), p<0.001] compared to SHIP-TREND and for obesity [0.7 (0.5–0.9), p=0.01], hypertension [0.4 (0.3–0.5), p<0.001] and HLP [0.4 (0.3–0.6), p<0.001] compared to DEGS. In cohort 2, ORs were significantly lower for HLP compared to both SHIP-TREND [0.4 (0.2–0.7), p=0.001] and DEGS [0.3 (0.2–0.5), p<0.001] and for hypertension [0.7 (0.4–0.9), p=0.04] compared to SHIP-TREND. In patients with SAI from cohort 2, ORs for DM2 [2.5 (1.3–4.9) p=0.009], hypertension [2.5 (1.4–4.5), p=0.002] and obesity [1.9 (1.1–3.1), p=0.02] were significantly higher compared to DEGS, whereas ORs for HLP were significantly lower compared to both SHIP [0.3 (0.1–0.6), p=0.002] and DEGS [0.3 (0.1–0.6), p<0.001]. In most of our AI patients treated with conventional glucocorticoid doses, the risk for T2DM, obesity, hypertension, and HLP was not increased. The number of hospitalizations was significantly higher in AI patients compared to controls, which might reflect increased susceptibility but also a more proactive management of concomitant diseases by physicians and patients.
Key words
adrenal insufficiency - hyperlipidaemia - hypertension - obesity, metabolic syndrome - cardiovascular risk factors - hospitalizationPublication History
Received: 12 July 2023
Accepted after revision: 11 October 2023
Accepted Manuscript online:
12 October 2023
Article published online:
03 January 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 Bergthorsdottir R, Leonsson-Zachrisson M, Odén A. et al. Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 2006; 91: 4849-4853
- 2 Burger-Stritt S, Pulzer A, Hahner S. Quality of life and life expectancy in patients with adrenal insufficiency: what is true and what is urban myth?. Front Horm Res 2016; 46: 171-183
- 3 Erichsen MM, Løvås K, Skinningsrud B. et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94: 4882-4890
- 4 Ngaosuwan K, Johnston DG, Godsland IF. et al. Increased mortality risk in patients with primary and secondary adrenal insufficiency. J Clin Endocrinol Metab 2021; 106: e2759-e2768
- 5 Ngaosuwan K, Johnston DG, Godsland IF. et al. Cardiovascular disease in patients with primary and secondary adrenal insufficiency and the role of comorbidities. J Clin Endocrinol Metab 2021; 106: 1284-1293
- 6 Filipsson H, Monson JP, Koltowska-Häggström M. et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006; 91: 3954-3961
- 7 Skov J, Sundström A, Ludvigsson JF. et al. Sex-specific risk of cardiovascular disease in autoimmune addison disease - a population-based cohort study. J Clin Endocrinol Metab 2019; 104: 2031-2040
- 8 Stewart PM, Biller BM, Marelli C. et al. Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J Clin Endocrinol Metab 2016; 101: 4843-4850
- 9 Quinkler M, Ekman B, Zhang P. et al. Mortality data from the European Adrenal Insufficiency Registry - patient characterization and associations. Clin Endocrinol 2018; 89: 30-35
- 10 Giordano R, Marzotti S, Balbo M. et al. Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J Endocrinol Invest 2009; 32: 917-923
- 11 Debono M, Ross RJ. What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?. Clin Endocrinol 2013; 78: 659-664
- 12 Bergthorsdottir R, Ragnarsson O, Skrtic S. et al. Visceral fat and novel biomarkers of cardiovascular disease in patients with Addison’s disease: a case-control study. J Clin Endocrinol Metab 2017; 102: 4264-4272
- 13 Frey KR, Kienitz T, Schulz J. et al. Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency. Endocr Connect 2018; 7: 811-818
- 14 Hahner S, Spinnler C, Fassnacht M. et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 2015; 100: 407-416
- 15 Gößwald A, Lange M, Kamtsiuris P. et al. [DEGS: German Health Interview and Examination Survey for Adults. A nationwide cross-sectional and longitudinal study within the framework of health monitoring conducted by the Robert Koch Institute]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 775-780
- 16 Völzke H. [Study of health in Pomerania (SHIP). Concept, design and selected results]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 790-794
- 17 Völzke H, Alte D, Schmidt CO. et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol 2011; 40: 294-307
- 18 Dineen R, Martin-Grace J, Ahmed KMS. et al. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study. Eur J Endocrinol 2021; 184: 253-265
- 19 Dunne FP, Elliot P, Gammage MD. et al. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clin Endocrinol (Oxf) 1995; 43: 623-629
- 20 Vulto A, Bergthorsdottir R, van Faassen M. et al. Residual endogenous corticosteroid production in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2019; 91: 383-390
- 21 Ebrahimi F, Widmer A, Wagner U. et al. Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients. Eur J Endocrinol 2019; 181: 701-709
- 22 Bancos I, Hazeldine J, Chortis V. et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. Eur J Endocrinol 2017; 176: 471-480